ULTRAGENYX PHARMACEUTICAL INC. Payments to Acquire Available-for-sale Securities
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Payments to Acquire Available-for-sale Securities of $648.52 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-10-27.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2020-10-27
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire available-for-sale securities for the quarter ending 2020-09-30 was $192.19M, a 28.83% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire available-for-sale securities for the quarter ending 2020-06-30 was $171.10M, a 14.60% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire available-for-sale securities for the quarter ending 2020-03-31 was $285.23M, a 9.39% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire available-for-sale securities for the quarter ending 2019-12-31 was $82.56M, a 747.00% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire available-for-sale securities for fiscal 2019 was $692.82M, a 35.90% increase from fiscal 2018.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire available-for-sale securities for fiscal 2018 was $509.80M, a 121.18% increase from fiscal 2017.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire available-for-sale securities for fiscal 2017 was $230.49M, a 47.91% decline from fiscal 2016.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire available-for-sale securities for fiscal 2016 was $442.49M, a 29.11% decline from fiscal 2015.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2020-09-30 | $192.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | $363.30M derived: sum of 2 quarters · filed 2020-10-27 | $648.52M 10-Q · filed 2020-10-27 | $731.08M derived: sum of 4 quarters · filed 2020-10-27 |
| 2020-06-30 | $171.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $456.33M 10-Q · filed 2020-07-30 | $538.89M derived: sum of 3 quarters · filed 2020-07-30 | $688.07M derived: sum of 4 quarters · filed 2020-10-27 |
| 2020-03-31 | $285.23M 10-Q · filed 2020-05-07 | $367.79M derived: sum of 2 quarters · filed 2020-05-07 | $516.97M derived: sum of 3 quarters · filed 2020-10-27 | $717.32M derived: sum of 4 quarters · filed 2020-10-27 |
| 2019-12-31 | $82.56M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $231.74M derived: sum of 2 quarters · filed 2020-10-27 | $432.09M derived: sum of 3 quarters · filed 2020-10-27 | $692.82M 10-K · filed 2020-02-14 |
| 2019-09-30 | $149.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | $349.53M derived: sum of 2 quarters · filed 2020-10-27 | $610.27M 10-Q · filed 2020-10-27 | $620.01M derived: sum of 4 quarters · filed 2020-10-27 |
| 2019-06-30 | $200.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $461.09M 10-Q · filed 2020-07-30 | $470.83M derived: sum of 3 quarters · filed 2020-07-30 | $562.20M derived: sum of 4 quarters · filed 2020-07-30 |
| 2019-03-31 | $260.73M 10-Q · filed 2020-05-07 | $270.48M derived: sum of 2 quarters · filed 2020-05-07 | $361.85M derived: sum of 3 quarters · filed 2020-05-07 | $509.70M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $9.75M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $101.11M derived: sum of 2 quarters · filed 2020-02-14 | $248.97M derived: sum of 3 quarters · filed 2020-02-14 | $509.80M 10-K · filed 2020-02-14 |
| 2018-09-30 | $91.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $239.22M derived: sum of 2 quarters · filed 2019-11-06 | $500.05M 10-Q · filed 2019-11-06 | $500.05M derived: sum of 4 quarters · filed 2020-02-14 |
| 2018-06-30 | $147.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $408.68M 10-Q · filed 2019-08-02 | $408.68M derived: sum of 3 quarters · filed 2020-02-14 | $431.96M derived: sum of 4 quarters · filed 2020-02-14 |
| 2018-03-31 | $260.83M 10-Q · filed 2019-05-07 | $260.83M derived: sum of 2 quarters · filed 2020-02-14 | $284.11M derived: sum of 3 quarters · filed 2020-02-14 | $403.79M derived: sum of 4 quarters · filed 2020-02-14 |
| 2017-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $23.28M derived: sum of 2 quarters · filed 2020-02-14 | $142.96M derived: sum of 3 quarters · filed 2020-02-14 | $230.49M 10-K · filed 2020-02-14 |
| 2017-09-30 | $23.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $142.96M derived: sum of 2 quarters · filed 2018-11-06 | $230.49M 10-Q · filed 2018-11-06 | $361.46M derived: sum of 4 quarters · filed 2019-02-20 |
| 2017-06-30 | $119.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $207.21M 10-Q · filed 2018-08-03 | $338.18M derived: sum of 3 quarters · filed 2019-02-20 | $426.57M derived: sum of 4 quarters · filed 2019-02-20 |
| 2017-03-31 | $87.53M 10-Q · filed 2018-05-08 | $218.49M derived: sum of 2 quarters · filed 2019-02-20 | $306.89M derived: sum of 3 quarters · filed 2019-02-20 | $411.89M derived: sum of 4 quarters · filed 2019-02-20 |
| 2016-12-31 | $130.97M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $219.37M derived: sum of 2 quarters · filed 2019-02-20 | $324.36M derived: sum of 3 quarters · filed 2019-02-20 | $442.49M 10-K · filed 2019-02-20 |
| 2016-09-30 | $88.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $193.39M derived: sum of 2 quarters · filed 2017-11-03 | $311.52M 10-Q · filed 2017-11-03 | $458.43M derived: sum of 4 quarters · filed 2018-02-21 |
| 2016-06-30 | $104.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $223.12M 10-Q · filed 2017-07-28 | $370.03M derived: sum of 3 quarters · filed 2018-02-21 | $604.95M derived: sum of 4 quarters · filed 2018-02-21 |
| 2016-03-31 | $118.13M 10-Q · filed 2017-05-05 | $265.04M derived: sum of 2 quarters · filed 2018-02-21 | $499.95M derived: sum of 3 quarters · filed 2018-02-21 | $665.10M derived: sum of 4 quarters · filed 2018-02-21 |
| 2015-12-31 | $146.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $381.82M derived: sum of 2 quarters · filed 2018-02-21 | $546.97M derived: sum of 3 quarters · filed 2018-02-21 | $624.23M 10-K · filed 2018-02-21 |
| 2015-09-30 | $234.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $400.07M derived: sum of 2 quarters · filed 2016-11-08 | $477.32M 10-Q · filed 2016-11-08 | $525.35M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $165.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $242.40M 10-Q · filed 2016-08-09 | $290.43M derived: sum of 3 quarters · filed 2017-02-17 | $322.08M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $77.25M 10-Q · filed 2016-05-10 | $125.28M derived: sum of 2 quarters · filed 2017-02-17 | $156.93M derived: sum of 3 quarters · filed 2017-02-17 | $198.23M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $48.03M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $79.67M derived: sum of 2 quarters · filed 2017-02-17 | $120.97M derived: sum of 3 quarters · filed 2017-02-17 | $208.97M 10-K · filed 2017-02-17 |
| 2014-09-30 | $31.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $72.94M derived: sum of 2 quarters · filed 2015-11-10 | $160.94M 10-Q · filed 2015-11-10 | $161.84M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | $41.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $129.30M 10-Q · filed 2015-08-14 | $130.19M derived: sum of 3 quarters · filed 2016-02-26 | |
| 2014-03-31 | $88.00M 10-Q · filed 2015-05-12 | $88.89M derived: sum of 2 quarters · filed 2016-02-26 | ||
| 2013-12-31 | $897.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $63.95M 10-K · filed 2016-02-26 | ||
| 2013-09-30 | $63.06M 10-Q · filed 2014-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |